央视网消息：2024年中国"三新"经济增加值占GDP的比重突破18%，助力经济发展，催生新就业岗位，展现出了强大的活力。 中国香港 文汇网：中国"三新"经济迅猛发展 "三新"经济是以新产业、新业态、新商业模式为核心内容的经济活动的集合。经核算，2024年中国"三新"经济增加值为242908亿元，比上 年增长6.7%，占GDP的比重为18.01%，占比逐年提高。"三新"经济催生了大量新就业岗位。中国日前发布第七批新职业与新工种，包括17个 新职业、42个新工种信息，其中人工智能、无人机及新消费领域的就业带动效应显著。 中国香港 中评网：工业经济运行"向稳向新向优" 面对更加严峻复杂的外部环境，中国的新型工业化加快推进，呈现出"向稳、向新、向优"的特点。产业创新平台建设持续推进，截至今年 6月底，中国已建成33家国家级制造业创新中心，241家中试平台纳入重点培育库。人工智能赋能作用持续加强，中国培育并开源人工智能大模 型，加快在电子、原材料、消费品等行业应用，形成了一批新模式新业态。接下来中国还将扎实推动科技创新和产业创新融合发展，加快实 施"人工智能+"行动，推动人形机器人、元宇宙、脑机接口等未来产业创新发展。 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-140 山东步长制药股份有限公司 关于控股子公司药品生产许可证变更的公告 注册地址：四川省泸州市泸县康乐大道西段480号 质量负责人：叶宇 生产地址和生产范围：四川省泸州市泸县康乐大道西段480号：治疗用生物制品（仅限注册申报使用） *** 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 法定代表人：杨春 山东步长制药股份有限公司（以下简称"公司"）近日获悉控股子公司四川泸州步长生物制药有限公司 （以下简称"泸州步长"）获得四川省药品监督管理局许可，同意泸州步长《药品生产许可证》生产范围 的变更，其他内容不变，现将相关情况公告如下： 许可证编号：川20220555 一、药品生产许可证相关情况 分类码：AsBs 企业名称：四川泸州步长生物制药有限公司 企业负责人：王舸 有效期至：2027年02月16日 由于医药产品具有高科技、高风险、高附加值的特点，药品的前期研发以及产品从研制、临床试验报批 到投产的周期长、环节多，容易受到一些不确定性因素的影响，敬请广大投资者谨慎 ...

Core Viewpoint - Venture capital has become a crucial lever for local economic development in China, with cities actively enhancing their investment environments and attracting quality investment institutions and innovative enterprises [1]. Group 1: City Venture Capital Activity - The 2024 China City Venture Capital Activity Index ranks Shanghai, Shenzhen, and Beijing as the top three cities, showing a significant lead over other cities [3]. - From 2018 to 2024, the overall trend of city venture capital activity indices has shown a fluctuating decline, with Beijing experiencing the most significant drop from 4302 in 2020 to 2166 [6]. - In terms of fundraising, Beijing ranks first due to its concentration of top financial institutions and national-level funding platforms, followed by Shanghai and Suzhou [8][11]. Group 2: Investment Trends - Shanghai leads the investment index in 2024, with Beijing and Shenzhen following closely behind, indicating a strong investment cluster in the Yangtze River Delta [12]. - The number of investment projects and financing events in Shanghai and Shenzhen accounts for 37% of the total in the top 10 cities, highlighting their roles as innovation engines [14]. Group 3: Exit Efficiency - Shenzhen has the highest exit index, breaking the previous dominance of Beijing and Shanghai in fundraising and investment, showcasing its exit efficiency advantage [15]. Group 4: City Innovation Power - The city innovation power index is closely linked to venture capital activity, with Beijing, Shanghai, and Shenzhen leading in both indices, indicating a symbiotic relationship between innovation and venture capital [19]. - Beijing's innovation power is bolstered by its national laboratories and top universities, while Shanghai benefits from its leading enterprises [20]. Group 5: Sector Concentration - The semiconductor and integrated circuit sector is the dominant investment area across major cities, with significant capital concentration [21]. - In terms of regional characteristics, Beijing leads in artificial intelligence, while Shenzhen excels in computer vision, reflecting the deep integration of local industrial resources and capital choices [22]. Group 6: Investment Activity in Key Cities - In 2024, Suzhou recorded 697 financing events with an estimated total financing amount of 272.67 billion, while Hangzhou had 577 events with 212.47 billion [22][23]. - Shenzhen's venture capital ecosystem is growing, with a notable increase in registered LP contributions, reaching 127.5 billion in 2024 [25].

在7月25日证券时报主办的第十三届创业投资大会暨全国创投协会联盟走进光明科学城活动现场上，证 券时报联合中国另类资产投资信息平台——执中，发布了《中国城市创投活力及城市创新力指数报 告》。 报告显示，2024年中国城市创投活力指数排名中，上海、深圳、北京稳居前三，持续领跑全国创投市 场；在城市创新力指数榜单上，北京、上海、深圳依旧占据前三甲。在热门赛道投融资的城市排名中， 杭州、苏州则凭借在六大战略性新兴产业赛道的活跃表现，双双跻身前五名。 具体来看，城市创投活力方面，2024年，上海、深圳、北京稳居前三且优势突出，与第四名及之后的城 市拉开较大差距，呈现"头部领跑，梯队分化"格局。从募资、投资和退出三个细分维度来看，北京凭借 集中的全国头部金融机构和国家级出资平台，募资指数位居第一。上海、苏州紧随其后，广深均位列前 五，其中苏州超越广深，南京与深圳基本持平。投资方面，2024年上海投资指数位居全国第一，北京、 深圳紧随其后。前10名城市投资指数差距较小，且以一线或新一线城市为主。退出方面，深圳退出指数 居首，打破了募资与投资领域北京、上海垄断前二的格局，彰显其退出效率优势。长三角表现强劲，苏 州、杭州均进入 ...

Core Viewpoint - The company is focusing on the development of its biopharmaceutical segment while managing costs and optimizing its product pipeline amidst a challenging market environment [2][5]. Group 1: Biopharmaceutical Development - Biopharmaceuticals are a key part of the company's dual strategy, facing high investment and long R&D cycles, with the industry currently experiencing a downturn [2]. - The company is seeing significant growth in business development and customer resource accumulation compared to 2023, but still falls short of scale production requirements [2]. - The company is controlling costs and expenses for its biopharmaceutical segments, with a focus on projects with promising clinical data, such as the BC006 monoclonal antibody injection nearing completion of Phase I clinical trials [2]. Group 2: Product Line Growth - The company’s second and third-tier products are showing a positive development trend, with continued support from the company [3]. - The company expects the sales growth of the Guaifenesin capsule to continue this year, while the Xuanyinning series aims for double-digit growth [3]. - Other products like Shuyuqing spray and Fufang Ganmaoling granules are also expected to maintain high growth rates, despite the absolute volume being lower than first-tier products [3]. Group 3: Sales Strategy and Financial Performance - The company is managing its sales expenses with a more precise allocation, focusing on second and third-tier products while maintaining a low sales expense ratio for first-tier products [4]. - The company reported a main revenue of 467 million yuan in Q1 2025, a decrease of 3.32% year-on-year, while net profit increased by 4.8% to 105 million yuan [5]. - The company’s gross margin stands at 77.76%, with a debt ratio of 27.69% [5]. Group 4: Market Outlook and Analyst Predictions - Analysts have provided various profit forecasts for the company, with net profit predictions for 2025 ranging from 471 million yuan to 512 million yuan [6]. - The company has seen a net outflow of 5.57 million yuan in financing over the past three months, indicating a decrease in financing balance [6].

Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases [5] - The company is involved in the commercialization and development of a portfolio of innovative medicines, including small molecules and biologics [5] - Pharming is headquartered in Leiden, the Netherlands, and operates in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific [5] Upcoming Financial Results - Pharming will report its preliminary (unaudited) financial results for the second quarter and first half of 2025 on July 31, 2025 [1] - A business update will also be provided during the same announcement [1] - Management will host a conference call and webcast for analysts and investors at 13:30 CEST/07:30 am EDT on the same day [1]

Core Viewpoint - The merger between BD and Waters aims to create a new leader in the life sciences and diagnostics sector, targeting the expanding precision medicine and biopharmaceutical markets with a total transaction value of approximately $17.5 billion [1][4][17]. Recent Developments and Future Outlook - In February 2025, BD announced plans to divest its biosciences and diagnostics business, followed by the merger agreement with Waters on July 14, 2025, with completion expected by the end of Q1 2026, pending regulatory approval [3]. - The global life sciences instrument market is projected to reach $85 billion by 2030, with a CAGR of approximately 5-6%, highlighting significant growth opportunities in precision medicine, biopharmaceuticals, and multiplex diagnostics [3]. Strategic Motives - The transaction reflects a strategic shift for both companies: BD focuses on core medical technologies, while Waters seeks to transform its business model from single instrument sales to recurring revenue in diagnostics and services [4][5]. - BD's divestiture aligns with its strategy to concentrate resources on core products like syringes and smart medical devices, which are closely tied to hospital workflows [4][7]. Industry Landscape and Market Opportunities - The merger occurs in a competitive environment where major players like Thermo Fisher and Danaher have expanded through acquisitions, creating pressure on mid-sized analytical instrument companies [5]. - The new company is expected to leverage BD's established presence in Asia, particularly in China and Japan, to enhance global expansion potential [3]. Technical Complementarity - The merger is significant for its technical complementarity, enabling a full chain capability from molecular analysis to cellular detection, which is crucial for biopharmaceutical development and personalized medicine [9][10]. Synergies and Collaborative Value - BD and Waters anticipate achieving approximately $200 million in cost synergies and $290 million in revenue synergies post-merger, but the focus is on the broader industry collaborative value rather than just financial metrics [11]. - The integration of technologies and market strategies is expected to enhance their competitive edge in the life sciences sector [12][16]. Product and Service Integration - The combined entity will offer a comprehensive solution that integrates molecular diagnostics and analytical capabilities, addressing the full spectrum of biopharmaceutical research and clinical validation needs [15]. - The merger allows for the development of complex multiplex testing products, enhancing diagnostic speed and accuracy [15]. Conclusion - The merger between BD and Waters represents a transformative move in the life sciences and diagnostics industry, positioning the new company as a key player in advancing precision medicine and biopharmaceutical innovation [17].

A股上证指数重返3400点，日内涨0.44%，CRO概念、生物制药、稀土概念等涨幅居前，两市超3900家 个股上涨。 ...

Investment Rating - The investment rating for the company is "Buy" [7] Core Viewpoints - The report is optimistic about the commercialization prospects of the company's products, including the monoclonal antibody "Sai Li Qi" and the bispecific antibodies GR2002 and GR1803, anticipating data readouts that could enhance valuation [1] - The company achieved significant revenue growth in 2024, with total revenue reaching 30.10 million yuan, and a slight narrowing of net losses to 797 million yuan [1] - The company has a differentiated pipeline with key products progressing steadily, including the approval of Sai Li Qi for moderate to severe plaque psoriasis and ankylosing spondylitis [1][2] Financial Performance - In Q1 2025, the company reported revenue of 20.16 million yuan and a net loss of 121 million yuan, with R&D expenses at 10.30 million yuan [1] - Revenue projections for 2025-2027 are estimated at 199 million yuan, 533 million yuan, and 1.07 billion yuan respectively, reflecting a strong growth trajectory [4][6] - The company maintains high R&D expenditure, with 610 million yuan in 2024, indicating a commitment to innovation [1] Pipeline Development - The GR1802 monoclonal antibody is progressing through clinical trials for multiple indications, with significant market potential [2] - The GR1801 rabies virus antibody is currently under review for market approval, with promising commercial prospects [2] - Other pipeline products, including GR2001 and GR1803, are advancing through clinical stages and partnerships, demonstrating the company's innovative capabilities [3]

Summary of Xeris Biopharma Holdings (XERS) 2025 Investor Day Company Overview - Xeris Biopharma Holdings is positioned for significant transformation and growth, focusing on three commercial products: Gvoke, KEVEYIS, and Recorlev, which address critical unmet medical needs in patients with diabetes, primary periodic paralysis, and hypercortisolism respectively [9][10] - The company is preparing to launch a new product, XP-8121, targeting hypothyroidism, which is expected to meet a significant unmet need in the market [11][15] Financial Performance - Xeris anticipates total revenue between $260 million to $275 million, with a positive adjusted EBITDA and 85% gross margins, indicating financial stability and self-sustainability [14][17] - Recorlev is projected to reach $1 billion in annual net revenue within the next ten years, serving as a growth engine for the company [19][15] Product Insights Recorlev - Recorlev is designed for treating hypercortisolism in patients with Cushing's syndrome, with a unique mechanism that normalizes cortisol levels [20][32] - The product is expected to address significant unmet needs and is positioned to generate sustainable long-term cash flow [21][19] - Clinical studies have shown that Recorlev can improve various health markers, including blood glucose levels, BMI, and cholesterol levels [34][33] XP-8121 - XP-8121 is a new formulation for hypothyroidism, utilizing proprietary XEROSOL technology for a once-weekly subcutaneous injection, which aims to provide consistent control of thyroid hormone levels [63][74] - The product addresses challenges associated with oral levothyroxine therapy, such as absorption issues and the need for frequent monitoring [70][72] Market Dynamics - The market for hypercortisolism is evolving, with increased awareness and screening for Cushing's syndrome, which is expected to drive demand for Recorlev [26][41] - The hypothyroidism market has not seen significant innovation in nearly fifty years, creating a substantial opportunity for XP-8121 [63][64] Clinical Perspectives - Experts highlighted the complexities of diagnosing and treating Cushing's syndrome, emphasizing the need for a comprehensive approach to patient care [47][50] - The burden of managing hypothyroidism is significant, with many patients experiencing inconsistent control due to various factors, including dietary influences and medication interactions [70][89] Strategic Initiatives - Xeris plans to expand its sales force and invest in market education to enhance the understanding of hypercortisolism and the value of Recorlev [36][39] - The company aims to partner with healthcare professionals to improve screening and treatment guidelines for both hypercortisolism and hypothyroidism [39][38] Conclusion - Xeris Biopharma is on a growth trajectory with a strong product pipeline and a commitment to addressing unmet medical needs in endocrinology, positioning itself as a leader in the biopharmaceutical space [18][15]